Evogene Ltd.

How big is Evogene Ltd.?

As of Jun 18, Evogene Ltd. has a market capitalization of 10.48 million, with net sales of 6.76 million and a net profit of -17.21 million over the latest four quarters. Shareholder's funds are at -1.45 million, and total assets amount to 39.86 million.

As of Jun 18, Evogene Ltd. has a market capitalization of 10.48 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 6.76 million, while the sum of Net Profit for the same period is -17.21 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at -1.45 million and Total Assets at 39.86 million.

What does Evogene Ltd. do?

Evogene Ltd. is a biotechnology company focused on enhancing crop productivity, classified as a micro-cap with a market cap of $10.48 million. As of March 2025, it reported net sales of $2 million and a net loss of $3 million.

Overview:<BR>Evogene Ltd. is a biotechnology company focused on improving crop productivity within the Pharmaceuticals & Biotechnology industry, classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 2 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 10.48 Million (Micro Cap)<BR><BR>Key Metrics:<BR>Debt Equity: 2.52 <BR>Return on Equity: 471.82% <BR>Price to Book: -2.87 <BR><BR>Contact Details:<BR>Address: 13 Gad Feinstein st., Park Rehovot P.O.B 2100 REHOVOT None : 7612002 <BR>Tel: 972 8 9311900 <BR>Fax: 972 8 9466724 <BR>Website: http://www.evogene.com/

Who are in the management team of Evogene Ltd.?

As of March 2022, the management team of Evogene Ltd. includes Mr. Martin Gerstel (Chairman), Dr. Adrian Percy, Prof. Oded Shoseyov, Ms. Sarit Firon, Mr. Ziv Kop, and Dr. Kinneret Livnat Savitsky, comprising both directors and independent directors.

As of March 2022, the management team of Evogene Ltd. includes the following individuals:<BR><BR>- Mr. Martin Gerstel, Chairman of the Board<BR>- Dr. Adrian Percy, Director<BR>- Prof. Oded Shoseyov, Director<BR>- Ms. Sarit Firon, Independent Director<BR>- Mr. Ziv Kop, Independent Director<BR>- Dr. Kinneret Livnat Savitsky, Independent Director<BR><BR>This team comprises a mix of directors and independent directors, contributing to the governance and strategic direction of the company.

Should I buy, sell or hold Evogene Ltd.?

Is Evogene Ltd. overvalued or undervalued?

As of August 31, 2022, Evogene Ltd. is considered a risky investment due to its negative price-to-book value of -2.01, low EV to EBIT and EV to EBITDA ratios, a valuation ratio significantly below industry average, and a year-to-date return of -34.60%, which underperforms the S&P 500's 12.22%.

As of 31 August 2022, the valuation grade for Evogene Ltd. moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company appears to be overvalued given its negative price-to-book value of -2.01, an EV to EBIT ratio of 0.08, and an EV to EBITDA ratio of 0.09, which suggest that the market is pricing the stock unfavorably compared to its earnings potential. <BR><BR>In comparison to peers, Evogene Ltd. has a valuation ratio of -0.7507, which is notably lower than the industry average. This further reinforces the notion that the company is not positioned favorably within its sector. Additionally, the stock has underperformed significantly against the S&P 500, with a year-to-date return of -34.60% compared to the index's 12.22%, highlighting the challenges facing the company in the current market environment.

Is Evogene Ltd. technically bullish or bearish?

As of February 21, 2025, Evogene Ltd. shows a mildly bearish trend with a price of 1.22, underperforming the S&P 500 significantly with year-to-date and one-year returns of -34.60% and -55.36%, respectively.

As of 21 February 2025, the technical trend for Evogene Ltd. has changed from bearish to mildly bearish. The current price is 1.22, showing slight movement from the previous close of 1.21. Despite this minor uptick, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -34.60% compared to the S&P 500's 12.22%, and a one-year return of -55.36% versus 17.14%. This indicates a weak technical stance overall.